

Author index

Volume 40 (1996)

- Alim, T.N. 40, 173
 Alterman, A.I. 40, 227
 Anthony, J.C. 40, 9, 159
 Arndt, I.O. 40, 125
 Ascher, J.A. 40, 125
 Avants, S.K. 40, 125
- Badger, G.J. 40, 195
 Balster, R.L. 40, 81
 Barrio, G. 40, 185, 249
 Bauer, L.O. 40, 203
 Beckson, M. 40, 125
 Bickel, W.K. 40, 195
 Bigelow, G.E. 40, 17, 27, 115
 Boening, J. 40, 49
 Bourland, J.A. 40, 111
 Bridge, P. 40, 125
 Budney, A.J. 40, 195
 Burgess, K. 40, 37
 Bux Jr., D.A. 40, 63
- Canteras, M. 40, 151
 Cherpitel, C.J. 40, 133
 Chutuape, M.A.D. 40, 115
 Claunch, A.E. 40, 37
 Compton III, W.M. 40, 103
 Copeland, J. 40, 211
 Corcoran, K.J. 40, 221
 Cornish, J. 40, 125
 Cottler, L.B. 40, 103
- Deutsch, S.I. 40, 173
 Drieze, J.M. 40, 87
 de la Fuente, L. 40, 185, 249
 de Vos, J.W. 40, 181
- Easton, C. 40, 203
 Eissenberg, T. 40, 17, 27
 Ensminger, M.E. 40, 159
 Escobar, F. 40, 151
 Espí, F. 40, 151
- Falk, J.L. 40, 241
 French, E.D. 40, 111
 French, J.F. 40, 63
- Gilmore-Thomas, K. 40, 235
 Goldstein, A. 40, 139
- Group for the Study of the purity of
 seized drugs. 40, 185
- Ham, I. 40, 37
 Hardwick, W.C. 40, 1
 Herrera, J. 40, 139
 Higgins, S.T. 40, 195
 Ho, K.K. 40, 37
 Huffman, J.W. 40, 81
- Iguchi, M.Y. 40, 63
- Jakob, F. 40, 49
 Johnson, E.O. 40, 159
 Johnson, R.E. 40, 17, 27
 Jones, J.A. 40, 37
- Kosten, T.R. 40, 125
 Kouri, E.M. 40, 73
 Kranzler, H.R. 40, 55
 Kushner, H. 40, 63
- Lake, J.R. 40, 37
 Lau, C.E. 40, 241
 Li, S.-H. 40, 125
 Lidz, V. 40, 63
 Liebson, I.A. 40, 17, 27
 Lindquist, T. 40, 173
 Ling, W. 40, 125
 Liu, J. 40, 37
 Lukas, S.E. 40, 73, 87
- Mager, D.E. 40, 103
 Malin, D.H. 40, 37
 Margolin, A. 40, 125
 Martin, B.R. 40, 81
 Maurer, C. 40, 49
 McClure, G.Y.H. 40, 1
 McKay, J.R. 40, 227
 McLaughlin, L. 40, 55
 McLellan, A.T. 40, 227
 McMillan, D.E. 40, 1, 235
 Mello, N.K. 40, 87
 Mendelson, J.H. 40, 87
 Menger, F. 40, 165
 Morel, J. 40, 37
 Mulvaney, F.D. 40, 227
- Oberlaender, F.A. 40, 165
 Oliva, P.S. 40, 73
 Ollo, C. 40, 173
- Payza, K. 40, 37
 Petronis, K.R. 40, 9
 Platt, J.J. 40, 63
 Platz, W.E. 40, 165
 Pope Jr., H.G. 40, 73
- Ray, S.M. 40, 43
 Regidor, E. 40, 249
 Rodriguez, C. 40, 249
 Roll, J.M. 40, 195
 Royuela, L. 40, 185
- Saavedra, P. 40, 185
 Saunders, S.S. 40, 43
 Schoener, E.P. 40, 43
 Schütz, C.G. 40, 159
 Schwerin, M.J. 40, 221
 Shillington, A.M. 40, 103
 Shivapuja, B.G. 40, 43
 Silverman, K. 40, 115
 Siris, A. 40, 241
 Smith, D.A. 40, 37
 Stevens, P.A. 40, 37
 Stitzer, M.L. 40, 17, 27, 115
 Stone, J. 40, 55
 Strain, E.C. 40, 17, 27
 Svikis, D.S. 40, 115
 Swift, W. 40, 211
- Thome, J. 40, 49
- Ufkes, J.G.R. 40, 181
- Vicente, J. 40, 185
 van Brussel, G.H.A. 40, 181
 van den Brink, W. 40, 181
- Wiesbeck, G.A. 40, 49
 Wiley, J.L. 40, 81
 Wilkins, J. 40, 125

Subject index

Volume 40 (1996)

α_1 -Adrenergic receptor antagonist; Cocaine action; Compound action potential; Prazosin; Cochlea 40, 43

Abusers; Recall; Substance abuse reports; Agreement rates 40, 103

Academic achievement; Substance abuse; Women; Unemployment; Occupational interests; Employment assessments 40, 115

Acceptability; Buprenorphine; Clinical trial; Placebo; Efficacy 40, 17

Accidents; Alcohol; Cocaine; Heroin 40, 249

Addiction; Cocaine; Methadone; Pharmacotherapy; Bupropion 40, 125

Addiction; Methadone; Methadone maintenance therapy; Craving; Experience sampling method; Pharmacokinetics; Self-report enquiries 40, 181

Adolescent; Inhalants; Heroin; Longitudinal; Epidemiology 40, 159

Age; Illicit drugs; Survival data analysis; Epidemiology 40, 9

Aggression; Anabolic-androgenic steroids; Testosterone cypionate; Male volunteers 40, 73

Agreement rates; Recall; Substance abuse reports; Abusers 40, 103

Alcohol; Accidents; Cocaine; Heroin 40, 249

Alcohol; Cocaine; Evoked potentials; Electroencephalogram (EEG) 40, 203

Alcohol Dependence; German Mental Health Legislation; Predictors for involuntary committal 40, 165

Alcoholism; Diagnosis; Primary health care; Diagnostic tests; Questionnaires; Clinical markers; Biological markers 40, 151

Alcoholism; Family history; D2 dopamine receptor sensitivity; Blunted growth hormone response; Apomorphine 40, 49

Alternate-day dosing; Buprenorphine; Drug abuse; Clinical trial; Opioid dependence; Efficacy 40, 27

Anabolic steroids; Beliefs; Expectancy; Bodybuilder; Drug-use 40, 221

Anabolic-androgenic steroids; Aggression; Testosterone cypionate; Male volunteers 40, 73

Antioptive peptides; Neuropeptide FF; Opiate dependence; Opiate abstinence syndrome; Morphine; Naloxone; Dansyl compounds 40, 37

Apomorphine; Alcoholism; Family history; D2 dopamine receptor sensitivity; Blunted growth hormone response 40, 49

Attrition rates; Cocaine dependence; Hospital treatment 40, 227

Beliefs; Anabolic steroids; Expectancy; Bodybuilder; Drug-use 40, 221

Biological markers; Alcoholism; Diagnosis; Primary health care; Diagnostic tests; Questionnaires; Clinical markers 40, 151

Blunted growth hormone response; Alcoholism; Family history; D2 dopamine receptor sensitivity; Apomorphine 40, 49

Bodybuilder; Anabolic steroids; Beliefs; Expectancy; Drug-use 40, 221

Buprenorphine; Clinical trial; Placebo; Efficacy; Acceptability 40, 17

Buprenorphine; Cocaine; Drug abuse; Drug self-administration; Rhesus monkey; Schedule-controlled behavior; Drug abuse treatment 40, 87

Buprenorphine; Drug abuse; Clinical trial; Opioid dependence; Alternate-day dosing; Efficacy 40, 27

Bupropion; Cocaine; Methadone; Pharmacotherapy; Addiction 40, 125

Chicano; Heroin addicts; Methadone treatment; Follow-up; Mortality; Criminality 40, 139

Cigarettes; Cocaine; Smokers; Non-smokers 40, 195

Clinical markers; Alcoholism; Diagnosis; Primary health care; Diagnostic tests; Questionnaires; Biological markers 40, 151

Clinical trial; Buprenorphine; Drug abuse; Opioid dependence; Alternate-day dosing; Efficacy 40, 27

Clinical trial; Buprenorphine; Placebo; Efficacy; Acceptability 40, 17

CNS depressants; Δ^9 -tetrahydrocannabinol; WIN 55212-2; Indoles; Drug discrimination 40, 81

Cocaine; Accidents; Alcohol; Heroin 40, 249

Cocaine; Alcohol; Evoked potentials; Electroencephalogram (EEG) 40, 203

Cocaine; Buprenorphine; Drug abuse; Drug self-administration; Rhesus monkey; Schedule-controlled behavior; Drug abuse treatment 40, 87

Cocaine; Cigarettes; Smokers; Non-smokers 40, 195

Cocaine; Crack; IQ; Neuropsychology; Cognition 40, 173

Cocaine; Methadone; Pharmacotherapy; Addiction; Bupropion 40, 125

Cocaine; Self-administration; Remoxipride; Progressive-ratio; Reinforcement 40, 111

Cocaine action; Compound action potential; Prazosin; α_1 -Adrenergic receptor antagonist; Cochlea 40, 43

Cocaine dependence; Hospital treatment; Attrition rates 40, 227

Cocaine self-administration; Schedule-induced behavior; Oral cocaine lidocaine; Stimulus control 40, 241

Cochlea; Cocaine action; Compound action potential; Prazosin; α_1 -Adrenergic receptor antagonist 40, 43

Cognition; Crack; Cocaine; IQ; Neuropsychology 40, 173

Compound action potential; Cocaine action; Prazosin; α_1 -Adrenergic receptor antagonist; Cochlea 40, 43

Crack; Cocaine; IQ; Neuropsychology; Cognition 40, 173

Craving; Methadone; Addiction; Methadone maintenance therapy; Experience sampling method; Pharmacokinetics; Self-report enquiries 40, 181

Criminality; Heroin addicts; Methadone treatment; Chicano; Follow-up; Mortality 40, 139

Δ^9 -tetrahydrocannabinol; WIN 55212-2; CNS depressants; Indoles; Drug discrimination 40, 81

D2 dopamine receptor sensitivity; Alcoholism; Family history; Blunted growth hormone response; Apomorphine 40, 49

Danazol compounds; Neuropeptide FF; Antiopeptide peptides; Opiate dependence; Opiate abstinence syndrome; Morphine; Naloxone 40, 37

Diagnosis; Alcoholism; Primary health care; Diagnostic tests; Questionnaires; Clinical markers; Biological markers 40, 151

Diagnostic tests; Alcoholism; Diagnosis; Primary health care; Questionnaires; Clinical markers; Biological markers 40, 151

Drug abuse; Buprenorphine; Clinical trial; Opioid dependence; Alternate-day dosing; Efficacy 40, 27

Drug abuse; Buprenorphine; Cocaine; Drug self-administration; Rhesus monkey; Schedule-controlled behavior; Drug abuse treatment 40, 87

Drug abuse treatment; Buprenorphine; Cocaine; Drug abuse; Drug self-administration; Rhesus monkey; Schedule-controlled behavior 40, 87

Drug discrimination; Δ^9 -tetrahydrocannabinol; WIN 55212-2; CNS depressants; Indoles 40, 81

Drug self-administration; Buprenorphine; Cocaine; Drug abuse; Rhesus monkey; Schedule-controlled behavior; Drug abuse treatment 40, 87

Drug-use; Anabolic steroids; Beliefs; Expectancy; Bodybuilder 40, 221

Drugs of abuse; Screening; Immunoassay; Point-of-care 40, 55

Efficacy; Buprenorphine; Clinical trial; Placebo; Acceptability 40, 17

Efficacy; Buprenorphine; Drug abuse; Clinical trial; Opioid dependence; Alternate-day dosing 40, 27

Electroencephalogram (EEG); Cocaine; Alcohol; Evoked potentials 40, 203

Emergency room; Rapid Alcohol Problems Screen; Problem drinking; Intervention 40, 133

Employment assessments; Substance abuse; Women; Unemployment; Academic achievement; Occupational interests 40, 115

Epidemiology; Age; Illicit drugs; Survival data analysis 40, 9

Epidemiology; Inhalants; Heroin; Longitudinal; Adolescent 40, 159

Ethanol; Running wheel; Rats 40, 1

Evoked potentials; Cocaine; Alcohol; Electroencephalogram (EEG) 40, 203

Expectancy; Anabolic steroids; Beliefs; Bodybuilder; Drug-use 40, 221

Experience sampling method; Methadone; Addiction; Methadone maintenance therapy; Craving; Pharmacokinetics; Self-report enquiries 40, 181

Family history; Alcoholism; D2 dopamine receptor sensitivity; Blunted growth hormone response; Apomorphine 40, 49

Follow-up; Heroin addicts; Methadone treatment; Chicano; Mortality; Criminality 40, 139

German Mental Health Legislation; Alcohol Dependence; Predictors for involuntary committal 40, 165

Heroin; Accidents; Alcohol; Cocaine 40, 249

Heroin; Inhalants; Longitudinal; Epidemiology; Adolescent 40, 159

Heroin; Purity; Route of administration; Intravenous; Spain 40, 185

Heroin addicts; Methadone treatment; Chicano; Follow-up; Mortality; Criminality 40, 139

- HIV seropositivity**; Substance abuse; Intravenous; Risk factors; Risk models; Replication study 40, 63
- Hospital treatment**; Cocaine dependence; Attrition rates 40, 227
- Illicit drugs**; Age; Survival data analysis; Epidemiology 40, 9
- Immunoassay**; Drugs of abuse; Screening; Point-of-care 40, 55
- Indoles**; Δ^9 -tetrahydrocannabinol; WIN 55212-2; CNS depressants; Drug discrimination 40, 81
- Inhalants**; Heroin; Longitudinal; Epidemiology; Adolescent 40, 159
- Intervention**; Rapid Alcohol Problems Screen; Problem drinking; Emergency room 40, 133
- Intravenous**; Heroin; Purity; Route of administration; Spain 40, 185
- Intravenous**; Substance abuse; HIV seropositivity; Risk factors; Risk models; Replication study 40, 63
- IQ**; Crack; Cocaine; Neuropsychology; Cognition 40, 173
- Longitudinal**; Inhalants; Heroin; Epidemiology; Adolescent 40, 159
- Male volunteers**; Aggression; Anabolic-androgenic steroids; Testosterone cypionate 40, 73
- Methadone**; Addiction; Methadone maintenance therapy; Craving; Experience sampling method; Pharmacokinetics; Self-report enquiries 40, 181
- Methadone**; Cocaine; Pharmacotherapy; Addiction; Bupropion 40, 125
- Methadone**; Opioid craving; Visual analog scales 40, 235
- Methadone maintenance therapy**; Methadone; Addiction; Craving; Experience sampling method; Pharmacokinetics; Self-report enquiries 40, 181
- Methadone treatment**; Heroin addicts; Chicano; Follow-up; Mortality; Criminality 40, 139
- Morphine**; Neuropeptide FF; Antioptive peptides; Opiate dependence; Opiate abstinence syndrome; Naloxone; Dansyl compounds 40, 37
- Mortality**; Heroin addicts; Methadone treatment; Chicano; Follow-up; Criminality 40, 139
- Naloxone**; Neuropeptide FF; Antioptive peptides; Opiate dependence; Opiate abstinence syndrome; Morphine; Dansyl compounds 40, 37
- Neuropeptide FF**; Antioptive peptides; Opiate dependence; Opiate abstinence syndrome; Morphine; Naloxone; Dansyl compounds 40, 37
- Neuropsychology**; Crack; Cocaine; IQ; Cognition 40, 173
- Non-smokers**; Cocaine; Cigarettes; Smokers 40, 195
- Occupational interests**; Substance abuse; Women; Unemployment; Academic achievement; Employment assessments 40, 115
- Opiate abstinence syndrome**; Neuropeptide FF; Antioptive peptides; Opiate dependence; Morphine; Naloxone; Dansyl compounds 40, 37
- Opiate dependence**; Neuropeptide FF; Antioptive peptides; Opiate abstinence syndrome; Morphine; Naloxone; Dansyl compounds 40, 37
- Opioid craving**; Visual analog scales; Methadone 40, 235
- Opioid dependence**; Buprenorphine; Drug abuse; Clinical trial; Alternate-day dosing; Efficacy 40, 27
- Oral cocaine lidocaine**; Cocaine self-administration; Schedule-induced behavior; Stimulus control 40, 241
- Pharmacokinetics**; Methadone; Addiction; Methadone maintenance therapy; Craving; Experience sampling method; Self-report enquiries 40, 181
- Pharmacotherapy**; Cocaine; Methadone; Addiction; Bupropion 40, 125
- Placebo**; Buprenorphine; Clinical trial; Efficacy; Acceptability 40, 17
- Point-of-care**; Drugs of abuse; Screening; Immunoassay 40, 55
- Policy**; Women; Treatment 40, 211
- Prazosin**; Cocaine action; Compound action potential; α_1 -Adrenergic receptor antagonist; Cochlea 40, 43
- Predictors for involuntary commitment**; German Mental Health Legislation; Alcohol Dependence 40, 165
- Primary health care**; Alcoholism; Diagnosis; Diagnostic tests; Questionnaires; Clinical markers; Biological markers 40, 151
- Problem drinking**; Rapid Alcohol Problems Screen; Emergency room; Intervention 40, 133
- Progressive-ratio**; Cocaine; Self-administration; Remoxipride; Reinforcement 40, 111
- Purity**; Heroin; Route of administration; Intravenous; Spain 40, 185
- Questionnaires**; Alcoholism; Diagnosis; Primary health care; Diagnostic tests; Clinical markers; Biological markers 40, 151
- Rapid Alcohol Problems Screen**; Problem drinking; Emergency room; Intervention 40, 133
- Rats**; Ethanol; Running wheel 40, 1
- Recall**; Substance abuse reports; Abusers; Agreement rates 40, 103
- Reinforcement**; Cocaine; Self-administration; Remoxipride; Progressive-ratio 40, 111
- Remoxipride**; Cocaine; Self-administration; Progressive-ratio; Reinforcement 40, 111
- Replication study**; Substance abuse; Intravenous; HIV seropositivity; Risk factors; Risk models 40, 63
- Rhesus monkey**; Buprenorphine; Cocaine; Drug abuse; Drug self-administration; Schedule-controlled behavior; Drug abuse treatment 40, 87

Risk factors; Substance abuse; Intravenous; HIV seropositivity; Risk models; Replication study 40, 63

Risk models; Substance abuse; Intravenous; HIV seropositivity; Risk factors; Replication study 40, 63

Route of administration; Heroin; Purity; Intravenous; Spain 40, 185

Running wheel; Ethanol; Rats 40, 1

Schedule-controlled behavior; Buprenorphine; Cocaine; Drug abuse; Drug self-administration; Rhesus monkey; Drug abuse treatment 40, 87

Schedule-induced behavior; Cocaine self-administration; Oral cocaine lidocaine; Stimulus control 40, 241

Screening; Drugs of abuse; Immunoassay; Point-of-care 40, 55

Self-administration; Cocaine; Remoxipride; Progressive-ratio; Reinforcement 40, 111

Self-report enquiries; Methadone; Addiction; Methadone maintenance therapy; Craving; Experience sampling method; Pharmacokinetics 40, 181

Smokers; Cocaine; Cigarettes; Non-smokers 40, 195

Spain; Heroin; Purity; Route of administration; Intravenous 40, 185

Stimulus control; Cocaine self-administration; Schedule-induced behavior; Oral cocaine lidocaine 40, 241

Substance abuse; Intravenous; HIV seropositivity; Risk factors; Risk models; Replication study 40, 63

Substance abuse; Women; Unemployment; Academic achievement; Occupational interests; Employment assessments 40, 115

Substance abuse reports; Recall; Abusers; Agreement rates 40, 103

Survival data analysis; Age; Illicit drugs; Epidemiology 40, 9

Testosterone cypionate; Aggression; Anabolic-androgenic steroids; Male volunteers 40, 73

Treatment; Women; Policy 40, 211

Unemployment; Substance abuse; Women; Academic achievement; Occupational interests; Employment assessments 40, 115

Visual analog scales; Opioid craving; Methadone 40, 235

WIN 55212-2; Δ^9 -tetrahydrocannabinol; CNS depressants; Indoles; Drug discrimination 40, 81

Women; Substance abuse; Unemployment; Academic achievement; Occupational interests; Employment assessments 40, 115

Women; Treatment; Policy 40, 211

